The IMID Forum

The Immune-Mediated Inflammatory Disease Forum
undefined
Jan 22, 2024 • 25min

Author Interview: Professor Andrea Rubbert-Roth, 2023

Join Professor Andrea Rubbert-Roth, a doctor of rheumatology, as she discusses the incidence of malignancy in rheumatology patients, the impact of EMA guidance on Jack inhibitors prescribing in Switzerland, the use of UVA poova treatment, and the challenges of long-term immunosuppression after oncology treatment.
undefined
Dec 22, 2023 • 11min

Discussing Rheumatology: December 2023

Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that compare the efficacy and safety of JAK inhibitors as RA therapies. In our first paper, Shinya Hayashi and his colleagues carried out a retrospective study to compare the efficacy of JAK inhibitors in treating RA. For our second paper, Christina Charles-Schoeman and her colleagues compared the incidence of MACE and VTE in RA and PsA patients treated with upadacitinib, adalimumab and MTX.
undefined
Dec 22, 2023 • 27min

PsA Podcast: Impact of Biological Sex on Advanced Therapies & Upadacitinib-related Malignancies

Join Philip Mease, Professor at the University of Washington School of Medicine and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, and Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre, as they discuss two important topics from the world of contemporary PsA treatment. The first of the publications they will be reviewing sought to compare patient characteristics and efficacy and safety of advanced therapies between male and female patients with PsA participating in RCTs. They then go on to discuss a second publication describing malignancies in patients with a variety of rheumatic conditions treated with upadacitinib or active comparators.
undefined
Dec 4, 2023 • 33min

AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.
undefined
Dec 1, 2023 • 33min

AxSpA Podcast: Safety and Efficacy of Tofacitinib and Bimekizumab

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.
undefined
Dec 1, 2023 • 21min

PsA Podcast: Gender differences in treating PsA & safety of guselkumab in treating PsO and PsA

Join Peter Nash, Professor at the School of Medicine, Griffith University, and Director of the Rheumatology Research Unit on the Sunshine Coast, Australia, Philip Mease, Professor at the University of Washington School of Medicine, and Director of Rheumatology Research at the Swedish Medical Centre in Seattle, USA, as well as Laura Coates, an Associate Professor, NIHR clinician scientist and senior clinical research fellow at the Oxford Psoriatic Arthritis Centre as they discuss two intriguing aspects of the contemporary PsA treatment landscape. The first of the publications relates to the effects of gender on disease characteristics, treatment impact and treatment persistence. The second publication explores the long-term safety profile of guselkumab in the treatment of PsO and PsA.
undefined
Nov 23, 2023 • 10min

Discussing Rheumatology: November 2023

Join Professor Iain McInnes in this month's CSF Podcast, where he discusses the latest information and data in rheumatology. In this episode, he discusses two papers that look at the incidence of disease. The first paper, the GBD 2021 Other Musculoskeletal Disorders Collaborators systematically analysed the global burden of musculoskeletal disorders, and used these data to predict prevalence up to 2050 and the second paper, Yvette Meissner and her colleagues used the German RABBIT registry to investigate the relationship between MACE risk and JAK inhibitors, TNF inhibitors, and DMARDs. To access detailed summary slides for the papers discussed today, visit cytokinesignalling.com.
undefined
Nov 15, 2023 • 3min

ACR 2023 Highlights: Day 4

Join Sofia Ramiro as she goes through our top abstracts, posters, and presentations from Day 4 of ACR 2023 today (Wednesday 15 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
undefined
Nov 14, 2023 • 4min

ACR 2023 Highlights: Day 3

Join Grace Wright as she goes through our top abstracts, posters, and presentations from Day 3 of ACR 2023 today (Tuesday 14 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!
undefined
Nov 13, 2023 • 3min

ACR 2023 Highlights: Day 2

Join Laura Coates as she goes through our top abstracts, posters, and presentations from Day 2 of ACR 2023 today (Monday 13 November). They're all available right here on the CSF YouTube channel, so make sure you don't miss them!

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app